United Kingdom

Saumya Joseph

Pharmaceuticals drive J&J to better-than-expected quarterly profit

16 Apr 2019

Johnson & Johnson on Tuesday reported a first-quarter profit that exceeded Wall Street expectations on higher sales of its prescription medicines, including a double-digit increase for its psoriasis treatment Stelara, even as the company faces fierce competition for some of its other important drugs.

Catalent seeks slice of gene therapy market with Paragon buy

15 Apr 2019

Contract drugmaker Catalent Inc said on Monday it would buy privately held Paragon Bioservices Inc for $1.2 billion (916.4 million pounds) in cash, bolstering its capabilities to make gene therapy drugs for its biotech clients.

Teen cigarette smoking declining more slowly in rural U.S.

11 Apr 2019

(Reuters Health) - The odds of smoking for U.S. adolescents are 50 percent higher in rural areas than in urban areas, even as rates of teen smoking in both settings have fallen, a recent study found.

Amgen's postmenopausal osteoporosis drug gets FDA greenlight

09 Apr 2019

The U.S. Food and Drug Administration said on Tuesday it had approved Amgen Inc's osteoporosis treatment for postmenopausal women who are at high risk of fracture.

Alkermes says long-acting drugs could help schizophrenics stay on medication longer

09 Apr 2019

Alkermes Plc said on Tuesday its long-acting injectable therapy for schizophrenia has helped reduce symptoms and can become an effective option for ensuring patients stay on medication even after being discharged from hospital.

Regeneron forays into gene-silencing therapies with Alnylam tie-up

08 Apr 2019

Regeneron Pharmaceuticals Inc said it would invest $800 million in Alnylam Pharmaceuticals Inc to develop treatments for eye and central nervous system diseases using gene-silencing RNA interference (RNAi) technology.

Walgreens cuts 2019 profit forecast, hit by lower drug prices

02 Apr 2019

Walgreens Boots Alliance Inc shares fell 13 percent on Tuesday after the company cut its 2019 earnings forecast and reported a disappointing quarterly profit in the face of stubbornly low generic drug prices in a crowded market.

World News